Jazz Pharmaceuticals plc
US ˙ NasdaqGS ˙ IE00B4Q5ZN47

SecurityJAZZ / Jazz Pharmaceuticals plc
InstitutionXTX Topco Ltd
Latest Disclosed Ownership17,336 shares
Latest Disclosed Value $ 3,277,371
XTX Topco Ltd reports 166.95% increase in ownership of JAZZ / Jazz Pharmaceuticals plc

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 17,336 shares of Jazz Pharmaceuticals plc (US:JAZZ) valued at $3,277,371 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 6,494 shares of Jazz Pharmaceuticals plc. This represents a change in shares of 166.95% during the quarter. The current value of the position is $4,135,850 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 17,336 10,842 166.95 3,277 197.10 0.0570
2026-02-17 2025-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 6,494 6,494 1,104 0.0290
2025-08-12 2025-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -1,638 -100.00 0 -100.00
2025-05-08 2025-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 1,638 1,638 203 0.0104
2025-02-13 2024-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -11,631 -100.00 0 -100.00
2024-11-14 2024-09-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 11,631 4,245 57.47 1,296 64.34 0.0937
2024-08-12 2024-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 7,386 7,386 788 0.0675
2024-05-13 2024-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -6,604 -100.00 0 -100.00
2024-02-13 2023-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 6,604 1,045 18.80 812 12.93 0.1779
2023-11-13 2023-09-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 5,559 3,241 139.82 720 150.52 0.1229
2023-08-14 2023-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 2,318 811 53.82 287 30.45 0.0515
2023-05-12 2023-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 1,507 1,507 221 0.0462
2022-11-14 2022-09-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -1,326 -100.00 0 -100.00
2022-08-15 2022-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 1,326 1,326 207 0.0846
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.